PRCT vs. IRTC, AXNX, TNDM, NARI, ICUI, IART, ATEC, MMSI, LMAT, and NVCR
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include iRhythm Technologies (IRTC), Axonics (AXNX), Tandem Diabetes Care (TNDM), Inari Medical (NARI), ICU Medical (ICUI), Integra LifeSciences (IART), Alphatec (ATEC), Merit Medical Systems (MMSI), LeMaitre Vascular (LMAT), and NovoCure (NVCR). These companies are all part of the "surgical & medical instruments" industry.
PROCEPT BioRobotics (NASDAQ:PRCT) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability.
In the previous week, PROCEPT BioRobotics had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for PROCEPT BioRobotics and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.08 beat PROCEPT BioRobotics' score of 0.43 indicating that iRhythm Technologies is being referred to more favorably in the news media.
PROCEPT BioRobotics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.
iRhythm Technologies received 361 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. Likewise, 66.04% of users gave iRhythm Technologies an outperform vote while only 62.22% of users gave PROCEPT BioRobotics an outperform vote.
PROCEPT BioRobotics has higher earnings, but lower revenue than iRhythm Technologies. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 0.7% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
PROCEPT BioRobotics currently has a consensus target price of $61.20, suggesting a potential downside of 10.16%. iRhythm Technologies has a consensus target price of $134.00, suggesting a potential upside of 32.65%. Given iRhythm Technologies' higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than PROCEPT BioRobotics.
iRhythm Technologies has a net margin of -25.33% compared to PROCEPT BioRobotics' net margin of -66.12%. PROCEPT BioRobotics' return on equity of -41.35% beat iRhythm Technologies' return on equity.
Summary
iRhythm Technologies beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PROCEPT BioRobotics Competitors List
Related Companies and Tools
